Comparison Between 12 Versus 20 Weeks of Trimethoprim-sulfamethoxazole as Oral Eradication Treatment for Melioidosis: An Open-label, Pragmatic, Multicenter, Non-inferiority, Randomized Controlled Trial.

MLA

Anunnatsiri, Siriluck, et al. “Comparison Between 12 Versus 20 Weeks of Trimethoprim-Sulfamethoxazole as Oral Eradication Treatment for Melioidosis: An Open-Label, Pragmatic, Multicenter, Non-Inferiority, Randomized Controlled Trial.” Clinical Infectious Diseases, vol. 73, no. 11, Dec. 2021, pp. e3627–33. EBSCOhost, https://doi.org/10.1093/cid/ciaa1084.

APA

Anunnatsiri, S., Chaowagul, W., Teparrukkul, P., Chetchotisakd, P., Tanwisaid, K., Khemla, S., Narenpitak, S., Pattarapongsin, M., Kongsawasd, W., Pisuttimarn, P., Thipmontree, W., Mootsikapun, P., Chaisuksant, S., Chierakul, W., Day, N. P. J., & Limmathurotsakul, D. (2021). Comparison Between 12 Versus 20 Weeks of Trimethoprim-sulfamethoxazole as Oral Eradication Treatment for Melioidosis: An Open-label, Pragmatic, Multicenter, Non-inferiority, Randomized Controlled Trial. Clinical Infectious Diseases, 73(11), e3627–e3633. https://doi.org/10.1093/cid/ciaa1084

Chicago

Anunnatsiri, Siriluck, Wipada Chaowagul, Prapit Teparrukkul, Ploenchan Chetchotisakd, Kittisak Tanwisaid, Supphachoke Khemla, Surapong Narenpitak, et al. 2021. “Comparison Between 12 Versus 20 Weeks of Trimethoprim-Sulfamethoxazole as Oral Eradication Treatment for Melioidosis: An Open-Label, Pragmatic, Multicenter, Non-Inferiority, Randomized Controlled Trial.” Clinical Infectious Diseases 73 (11): e3627–33. doi:10.1093/cid/ciaa1084.